ULI HACKSELL, Ph.D., JOINS GLIONOVA AS CHAIRMAN OF THE BOARD
STOCKHOLM, JUNE 1, 2015 – Glionova Therapeutics, an oncology-focused biopharmaceutical company today announced that Dr. Uli Hacksell has joined its board of directors as chairman.
“It’s our privilege to welcome Dr. Hacksell on our board of directors.” said Eugen Steiner, M.D., Ph.D., Chief Executive Officer of Glionova Therapeutics. “With his vast experience he will be able to contribute greatly to our ability to advance GLN-1001 into clinical development with the aim of improving treatment for patients with glioblastoma“.
Dr. Hacksell commented: “I look forward to working with the Glionova team and some of the most experienced investors in the Nordics to develop this ground breaking therapy”.
Dr. Uli Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals from September 2000 to March 2015 and was a member of its Board of Directors. He joined ACADIA in 1999 as Executive Vice President of Drug Discovery. Under Dr. Hacksell’s leadership, ACADIA grew from a small startup to a fast growing biopharmaceutical company with an NDA submission for the internally developed Nuplazid, a potential blockbuster drug candidate, expected later this year. From 1991 to 1999, Dr.Hacksell held various executive positions at Astra, a pharmaceutical company, including Vice President of Drug Discovery and Technology, President of Astra Draco, one of Astra’s largest R&D subsidiaries, and Vice President of CNS Preclinical R&D at Astra Arcus, another Astra subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. Dr. Hacksell is a member of the Board of Uppsala University. He received a Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University.
About Glionova Therapeutics
Glionova Therapeutics is a privately held biopharmaceutical company focused on developing new therapies for cancer. The Company’s lead candidate, GLN-1001, is a first-in-class, orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells. Glioblastoma is the most common and most aggressive form of brain cancer, affecting roughly 2-7 in 100 000 individuals world-wide annually.
GLN-1001 is currently in preclinical development, where it has been shown to dramatically prolong survival in patient derived xenograft animal models of glioblastoma. Glionova aims to apply for orphan drug designation in both the United States and the European Union. Visit www.glionova.com for more information. http://www.glionova.com/
For further information, please contact:
Eugen Steiner, CEO Glionova Therapeutics.
Cell phone: +46 70 540 65 19.
Email: eugen.steiner@glionova.com
Source: Glionova
